Danaher (NYSE:DHR) shares rose before hours on first-quarter results that easily toppled the consensus forecast. The Washington, D.C.-based company posted profits of $1.7 billion, or $2.29 per share, on sales of $6.9 billion for the three months ended April 2, 2021, nearly tripling its bottom-line on sales growth of 57.9%. Adjusted to exclude one-time items, earnings […]
Danaher Corp.
3M, Abbott in top 50 of Fortune’s most admired companies list
Medtech giants 3M (NYSE:MMM) and Abbott (NYSE:ABT) made it into the top 50 of Fortune‘s 2021 World’s Most Admired Companies list. 3M — a manufacturing conglomerate that also has one of the largest medical device businesses in the world — came in at No. 24, up from No. 29 in the 2020 list. Abbott meanwhile was No. […]
Danaher rises on Street-beating Q4
Danaher (NYSE:DHR) shares ticked up this morning on fourth-quarter results that topped the consensus forecast. The Washington, D.C.-based company posted profits of $1.2 billion, or $1.66 per share, on sales of $6.8 billion for the three months ended Dec. 31, 2020, for a -4.8% bottom-line slide on sales growth of 38.9%. Adjusted to exclude one-time items, […]
The 10 largest medical device companies in the world
Even as the world’s largest medical device companies grapple with COVID-19 and the resulting recession, they’re doing important work to help humanity manage the crisis. Read on to find out more about the 10 largest companies in the Big 100, MassDevice and Medical Design & Outsourcing’s annual analysis of the worlds’ 100 largest medical device companies. […]
Cepheid wins EUA for COVID-19, flu, RSV combination test
Cepheid announced today that it received FDA emergency use authorization for its Xpert Xpress SARS-CoV-2/Flu/RSV diagnostic test. The Danaher Corp. (NYSE:DHR) subsidiary’s rapid molecular diagnostic test for detecting the viruses causing COVID-19, Flu A, Flu B and RSV infections in a single patient can be used in tandem with any of Cepheid’s GeneXpert systems across the […]
Danaher down on inline Q1 results
Danaher posted first-quarter results that were in line with the consensus on Wall Street. The Washington, D.C.-based company reported profits of $595.1 million, or 81¢ per share on sales of $4.3 billion for the three months ended March 31, for a bottom-line gain of 78.3% sales growth of 2.9% compared with Q1 2019. Adjusted to […]
Rainer M. Blair to move up to corner office at Danaher
Danaher (NYSE:DHR) announced today that EVP Rainer M. Blair will become CEO after Thomas P. Joyce Jr.’s retirement on Sept. 1. Joyce will stay on as a senior advisor at Danaher through February 28, 2021. “This announced transition comes at a time when Danaher has never been stronger or better positioned to compete given our attractive […]
GE closes $20b sale of BioPharma to Danaher
General Electric (NYSE:GE) announced that it completed the sale of its BioPharma business to Danaher (NYSE:DHR) for net proceeds totaling approximately $20 billion. Boston-based GE said in a news release that, under the agreeement, it received a total consideration worth $21.4 billion, with $21 billion in cash along with Danaher’s assumption of certain pension liabilities. After accounting for […]
5 companies on the front lines of the coronavirus fight
Nancy Crotti, Managing Editor and Danielle Kirsh, Senior Editor Amid the stock market roller-coaster ride that began last month, medtech companies that make devices and diagnostic tests vital to fighting COVID-19 may ultimately fare better than others, but it’s hard to tell until the virus peaks and people get back to work. At midafternoon today, […]
Cepheid wins emergency use nod from FDA for bedside coronavirus test
Danaher Corp. (NYSE:DHR) subsidiary Cepheid announced that it received emergency use authorization from the FDA for its bedside Xpert Xpress SARS-CoV-2 test for detecting the virus causing the COVID-19 outbreak. The rapid molecular diagnostic test is designed to detect the SARS-CoV-2 virus causing coronavirus while operating on any of Cepheid’s GeneXpert systems worldwide, with a detection […]
How will coronavirus affect medtech companies that rely on elective surgeries?
One thing is likely to hurt some medtech companies more than others during the coronavirus pandemic: an elective surgical procedure slowdown. This thought had begun to emerge last week among industry watchers, but a pair of tweets over the weekend gained thousands of “likes” and retweets. The American College of Surgeons called for hospitals to […]
